| Literature DB >> 34745982 |
Ning Li1,2, Yan Mo3, Chencui Huang3, Kai Han3, Mengna He1, Xiaolan Wang1, Jiaqi Wen1, Siyu Yang1, Haoting Wu1, Fei Dong1, Fenglei Sun3, Yiming Li3, Yizhou Yu3, Minming Zhang1, Xiaojun Guan1, Xiaojun Xu1.
Abstract
BACKGROUND: Brain invasion in meningioma has independent associations with increased risks of tumor progression, lesion recurrence, and poor prognosis. Therefore, this study aimed to construct a model for predicting brain invasion in WHO grade II meningioma by using preoperative MRI.Entities:
Keywords: atypical meningioma; brain invasion; magnetic resonance imaging; radiomics; semantic
Year: 2021 PMID: 34745982 PMCID: PMC8570084 DOI: 10.3389/fonc.2021.752158
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 6.244
Figure 1The flowchart of data inclusion and exclusion.
Figure 2Different ROI segmentation conditions are displayed in 2D and 3D in ITK-SNAP software, including the original image, the manually segmented tumoral ROI, and the semi-automatically segmented tumor-to-brain interface ROI. (A) Tumor located in anterior cranial fossa with overlap of non-brain tissues (i.e., bone) after 5 mm expansion, which is manually revised to only keep tumor-to-brain interface. (B) The same tumor with overlap of non-brain tissues (i.e., postorbital tissues) after 5 mm expansion, which is manually revised to only keep tumor-to-brain interface. (C) The same tumor without any overlap of non-brain tissues after 5 mm expansion. (D) 3D visualization. ROI, region of interest.
Figure 3Workflow of this study, which mainly composed of six steps: ROI segmentation, image preprocessing, feature extraction, feature selection, model building, and model comparative evaluation. ROI, region of interest.
Demographic information of the 284 patients.
| Index | Patients ( | ||
|---|---|---|---|
| Non-invasion group ( | Invasion group ( |
| |
|
| 57.1 ± 12.3 | 56.6 ± 11.5 | 0.745a |
|
| 42.8 ± 16.8 | 44.6 ± 14.5 | 0.358a |
|
| 31 (24–39.5) | 34 (25–41) | 0.226b |
|
| 0.843c | ||
| Female | 68 (61.3%) | 108 (62.4%) | |
| Male | 43 (38.7%) | 65 (37.6%) | |
|
| 0.000**c | ||
| Anterior cranial fossa | 7 (6.3%) | 38 (22.0%) | |
| Middle cranial fossa | 5 (4.5%) | 3 (1.7%) | |
| Posterior cranial fossa | 11 (9.9%) | 3 (1.7%) | |
| Sphenoid crest | 10 (9.0%) | 14 (8.1%) | |
| Saddle tubercle | 0 (0.0%) | 4 (2.3%) | |
| Lateral convexity | 44 (39.6%) | 78 (45.1%) | |
| Midline convexity | 24 (21.6%) | 20 (11.6%) | |
| Tentorium cerebelli | 7 (6.3%) | 9 (5.2%) | |
| Ventricle | 1 (0.9%) | 4 (2.3%) | |
| Other | 2 (1.8%) | 0 (0.0%) | |
|
| 0.073c | ||
| Single | 109 (98.2%) | 162 (93.6%) | |
| Multiple | 2 (1.8%) | 11 (6.4%) | |
|
| 59 (53.2%) | 105 (60.7%) | 0.209c |
|
| 47 (42.3%) | 67 (38.7%) | 0.544c |
|
| 43 (38.7%) | 96 (55.5%) | 0.006**c |
|
| 18 (16.2%) | 30 (17.3%) | 0.805c |
|
| 100 (90.1%) | 148 (85.5%) | 0.262c |
|
| 97 (87.4%) | 126 (72.8%) | 0.004**c |
|
| 4 (3.6%) | 6 (3.5%) | 1.000c |
|
| 1 (0.9%) | 3 (1.7%) | 0.948c |
|
| 0.200d | ||
| Hyperintense | 6 (5.4%) | 2 (1.2%) | |
| Isointense | 73 (65.8%) | 113 (65.3%) | |
| Hypointense | 32 (28.8%) | 58 (33.5%) | |
|
| 0.029d* | ||
| Hyperintense | 49 (44.1%) | 68 (39.3%) | |
| Isointense | 61 (55.0%) | 91 (52.6%) | |
| Isointense | 1 (0.9%) | 14 (8.1%) | |
|
| 0.325d | ||
| Mild | 15 (13.5%) | 31 (17.9%) | |
| Marked | 96 (86.5%) | 142 (82.1%) | |
|
| 0.689d | ||
| Uniformly | 41 (36.9%) | 68 (39.3%) | |
| Uneven | 70 (63.1%) | 105 (60.7%) | |
|
| 0.572d | ||
| Clear | 24 (21.6%) | 32 (18.5%) | |
| Unclear | 55 (49.5%) | 88 (50.9%) | |
| Indistinct | 32 (28.8%) | 53 (30.6%) | |
|
| 0.000**d | ||
| None | 38 (34.2%) | 10 (5.8%) | |
| Mild | 55 (49.5%) | 101 (58.4%) | |
| Marked | 18 (16.2%) | 62 (35.8%) | |
aTwo sample t-test.
bWilcoxon test.
cChi-square test.
dKruskal–Wallis H test.
*p < 0.05, **p < 0.01.
Demographic information of meningioma patients in the training set and test set.
| Index | Training set ( | Test set ( |
| ||||
|---|---|---|---|---|---|---|---|
| Non-invasion group ( | Invasion group ( |
| Non-invasion group ( | Invasion group ( |
| ||
|
| 57.1 ± 11.7 | 56.2 ± 12.2 | 0.564 | ||||
|
| 42.2 ± 16.4 | 45.6 ± 14.3 | 0.132 | 44.3 ± 17.7 | 42.3 ± 14.8 | 0.571 | 0.542 |
|
| 31 (24–39) | 34.8 (26–41) | 0.092 | 34.5 (24.3–41.3) | 34 (23.5–40.1) | 0.477 | 0.899 |
|
| 0.934 | 0.803 | 0.324 | ||||
| Female | 46 (59.7%) | 73 (60.3%) | 22 (64.7%) | 35 (67.3%) | |||
| Male | 31 (40.3%) | 48 (39.7%) | 12 (35.3%) | 17 (32.7%) | |||
|
| 0.010** | 0.053 | 0.769 | ||||
| Anterior cranial fossa | 5 (6.5%) | 27 (22.3%) | 2 (5.9%) | 11 (21.2%) | |||
| Middle cranial fossa | 4 (5.2%) | 3 (2.5%) | 1 (2.9%) | 0 (0.0%) | |||
| Posterior cranial fossa | 7 (9.1%) | 2 (1.7%) | 4 (11.8%) | 1 (1.9%) | |||
| Sphenoid crest | 8 (10.4%) | 11 (9.1%) | 2 (5.9%) | 3 (5.8%) | |||
| Saddle tubercle | 0 (0.0%) | 2 (1.7%) | 0 (0.0%) | 2 (3.8%) | |||
| Lateral convexity | 32 (41.6%) | 52 (43.0%) | 12 (35.3%) | 26 (50.0%) | |||
| Midline convexity | 15 (19.5%) | 16 (13.2%) | 9 (26.5%) | 4 (7.7%) | |||
| Tentorium cerebelli | 4 (5.2%) | 5 (4.1%) | 3 (8.8%) | 4 (7.7%) | |||
| Ventricle | 0 (0.0%) | 3 (2.5%) | 1 (2.9%) | 1 (1.9%) | |||
| Other | 2 (2.6%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | |||
|
| 0.162 | 0.932 | 1.000 | ||||
| Single | 76 (98.7%) | 113 (93.4%) | 33 (97.1%) | 49 (94.2%) | |||
| Multiple | 1 (1.3%) | 8 (6.6%) | 1 (2.9%) | 3 (5.8%) | |||
|
| 42 (54.5%) | 74 (61.2%) | 0.357 | 17 (50.0%) | 31 (59.6%) | 0.380 | 0.664 |
|
| 31 (40.3%) | 47 (38.8%) | 0.842 | 16 (47.1%) | 20 (38.5%) | 0.429 | 0.697 |
|
| 30 (39.0%) | 68 (56.2%) | 0.018* | 13 (38.2%) | 28 (53.8%) | 0.156 | 0.778 |
|
| 10 (13.0%) | 22 (18.2%) | 0.333 | 8 (23.5%) | 8 (15.4%) | 0.343 | 0.614 |
|
| 68 (88.3%) | 106 (87.6%) | 0.882 | 32 (94.1%) | 42 (80.8%) | 0.153 | 0.670 |
|
| 66 (85.7%) | 93 (76.9%) | 0.127 | 31 (91.2%) | 33 (63.5%) | 0.004** | 0.267 |
|
| 2 (2.6%) | 6 (5.0%) | 0.651 | 2 (5.9%) | 0 (0.0%) | 0.299 | 0.711 |
|
| 0 (0.0%) | 1 (0.8%) | 1.000 | 1 (2.9%) | 2 (3.8%) | 1.000 | 0.158 |
|
| 0.671 | 0.089d | 0.223 | ||||
| Hyperintense | 4 (5.2%) | 1 (0.8%) | 2 (5.9%) | 1 (1.9%) | |||
| Isointense | 47 (61.0%) | 79 (65.3%) | 26 (76.5%) | 34 (65.4%) | |||
| Hypointense | 26 (33.8%) | 41 (33.9%) | 6 (17.6%) | 17 (32.7%) | |||
|
| 0.069 | 0.897d | 0.749d | ||||
| Hyperintense | 37 (48.1%) | 45 (37.2%) | 12 (35.3%) | 23 (44.2%) | |||
| Isointense | 39 (50.6%) | 68 (56.2%) | 22 (64.7%) | 23 (44.2%) | |||
| Hypointense | 1 (1.3%) | 8 (6.6%) | 0 (0.0%) | 6 (11.5%) | |||
|
| 0.257 | 1.000d | 0.168 | ||||
| Mild | 11 (14.3%) | 25 (20.7%) | 4 (11.8%) | 6 (11.5%) | |||
| Marked | 66 (85.7%) | 96 (79.3%) | 30 (88.2%) | 46 (88.5%) | |||
|
| 0.987 | 0.451d | 0.789 | ||||
| Uniform | 30 (39.0%) | 47 (38.8%) | 11 (32.4%) | 21 (40.4%) | |||
| Uneven | 47 (61.0%) | 74 (61.2%) | 23 (67.6%) | 31 (59.6%) | |||
|
| 0.514 | 0.961d | 0.830 | ||||
| Clear | 19 (24.7%) | 21 (17.4%) | 5 (14.7%) | 11 (21.2%) | |||
| Unclear | 35 (45.5%) | 64 (52.9%) | 20 (58.8%) | 24 (46.2%) | |||
| Indistinct | 23 (29.9%) | 36 (29.8%) | 9 (26.5%) | 17 (32.7%) | |||
|
| 0.000** | 0.000**d | 0.587 | ||||
| None | 27 (35.1%) | 6 (5.0%) | 11 (32.4%) | 4 (7.7%) | |||
| Mild | 35 (45.5%) | 72 (59.5%) | 20 (58.8%) | 29 (55.8%) | |||
| Marked | 15 (19.5%) | 43 (35.5%) | 3 (8.8%) | 19 (36.5%) | |||
Two-sample t-test.
Wilcoxon test.
Chi-square analysis.
Kruskal–Wallis H test.
*p < 0.05, **p < 0.01.
Figure 4The Pearson correlation heat maps of radiomics features. (A) Sixty of the original 1,740 radiomics features of tumoral ROI; (B) 20 selected radiomics features of tumoral ROI; (C) 60 of the original 1,740 radiomics features of tumor-to-brain interface ROI; (D) 20 selected radiomics features of tumor-to-brain interface ROI. ROI, region of interest.
Figure 5Visualization of tumoral and tumor-to-brain interface significant radiomics features of brain invasion and non-invasion in patients with meningioma. The results show the differences between two ROIs in the high-throughput radiomics features. In meningioma with brain invasion, the signal in the tumor is more dense, and the texture signal intensity around the 5-mm tumor is higher, that is, the information complexity is higher. (A) Original_firstorder (pseudo-color image); (B) wavelet-LLH_gldm; (C) log-sigma-1-0-mm-_glcm; (D) lbp-m2_ngtdm; (E) log-sigma-3-0-mm-_glrlm; (F) wavelet-HHL_glszm. ROI, region of interest.
Statistics of all the selected radiomics features.
| Features | Weights | Mean | Standard deviation |
| Test | Feature source | Sort | Image |
|---|---|---|---|---|---|---|---|---|
| LoG-sigma-3-0-mm-3D_glrlm_ShortRunLowGrayLevelEmphasis2ROI | 0.1468 | 0.0069 | 0.0058 | 0.001* | W | Tumor-to-brain interface ROI | Texture | LoG |
| LBP-3D-m2_ngtdm_Complexity2ROI | −0.1455 | 3.8204 | 1.2285 | 0.004* | W | Tumor-to-brain interface ROI | Texture | LBP |
| exponential_gldm_SmallDependenceLowGrayLevelEmphasis2ROI | −0.1226 | 0.0199 | 0.0024 | 0.000* |
| Tumor-to-brain interface ROI | Texture | Exponential |
| square_gldm_SmallDependenceLowGrayLevelEmphasis2ROI | −0.1015 | 0.0228 | 0.0057 | 0.000* | W | Tumor-to-brain interface ROI | Texture | Square |
| logarithm_ngtdm_Busyness1ROI | 0.0942 | 0.0975 | 0.1218 | 0.000* | W | Tumor ROI | Texture | LoG |
| LoG-sigma-4-0-mm-3D_firstorder_Kurtosis2ROI | −0.0935 | 2.9566 | 0.8304 | 0.000* | W | Tumor-to-brain interface ROI | First-order | LoG |
| LoG-sigma-3-0-mm-3D_glcm_Correlation2ROI | 0.0923 | 0.9341 | 0.0101 | 0.000* | W | Tumor-to-brain interface ROI | Texture | LoG |
| LoG-sigma-3-0-mm-3D_glcm_Idmn2ROI | −0.0921 | 0.996 | 0.0016 | 0.007* |
| Tumor-to-brain interface ROI | Texture | LoG |
| logarithm_ngtdm_Strength1ROI | −0.0882 | 26.2279 | 32.0014 | 0.000* | W | Tumor ROI | Texture | LoG |
| LoG-sigma-1-0-mm-3D_glcm_InverseVariance1ROI | 0.0828 | 0.4085 | 0.0516 | 0.000* | W | Tumor ROI | Texture | LoG |
| LoG-sigma-3-0-mm-3D_glrlm_LongRunHighGrayLevelEmphasis1ROI | −0.0695 | 971.5188 | 765.1715 | 0.000* | W | Tumor ROI | Texture | LoG |
| LoG-sigma-1-0-mm-3D_glcm_Correlation1ROI | 0.0694 | 0.5867 | 0.0538 | 0.002 |
| Tumor ROI | Texture | LoG |
| LBP-3D-k_glrlm_RunVariance2ROI | 0.0655 | 18.9969 | 6.2895 | 0.007* | W | Tumor-to-brain interface ROI | Texture | LBP |
| original_shape_SurfaceVolumeRatio2ROI | −0.0643 | 0.3724 | 0.0438 | 0.006* |
| Tumor-to-brain interface ROI | Shape | Original image |
| logarithm_glcm_Correlation2ROI | 0.0636 | 0.7629 | 0.0834 | 0.000* |
| Tumor-to-brain interface ROI | Texture | LoG |
| LBP-3D-m2_glszm_LargeAreaLowGrayLevelEmphasis2ROI | 0.0614 | 86.305 | 63.3261 | 0.001* | W | Tumor-to-brain interface ROI | Texture | LBP |
| exponential_glcm_Correlation2ROI | 0.0581 | 0.7174 | 0.1598 | 0.000* | W | Tumor-to-brain interface ROI | Texture | Exponential |
| LoG-sigma-2-0-mm-3D_ngtdm_Strength2ROI | −0.0533 | 5.7185 | 6.7859 | 0.009* | W | Tumor-to-brain interface ROI | Texture | LoG |
| original_firstorder_Minimum1ROI | 0.0501 | −5.0574 | 41.7556 | 0.000* |
| Tumor ROI | First-order | Original image |
| wavelet-HH_glszm_SmallAreaEmphasis1ROI | −0.0495 | 0.7119 | 0.0341 | 0.000* |
| Tumor ROI | Texture | Wavelet |
| exponential_gldm_SmallDependenceLowGrayLevelEmphasis1ROI | −0.0473 | 0.0231 | 0.0067 | 0.000* | W | Tumor ROI | Texture | Exponential |
| exponential_gldm_LowGrayLevelEmphasis1ROI | −0.0462 | 0.4158 | 0.2573 | 0.000* | W | Tumor ROI | Texture | Exponential |
| LBP-3D-m2_firstorder_Skewness1ROI | −0.046 | −0.595 | 0.2577 | 0.000* | W | Tumor ROI | First-order | LBP |
| wavelet-LL_firstorder_Skewness1ROI | 0.0374 | −0.3226 | 0.5985 | 0.006* |
| Tumor ROI | First-order | Wavelet |
| LBP-3D-k_gldm_LargeDependenceHighGrayLevelEmphasis2ROI | 0.0365 | 61.6663 | 2.7931 | 0.000* |
| Tumor-to-brain interface ROI | Texture | LBP |
| original_firstorder_Minimum2ROI | 0.0357 | −46.631 | 32.7178 | 0.000* |
| Tumor-to-brain interface ROI | First-order | Original image |
| LBP-3D-m1_glszm_SmallAreaLowGrayLevelEmphasis1ROI | 0.0353 | 0.1478 | 0.026 | 0.008* |
| Tumor ROI | Texture | LBP |
| LBP-3D-k_glcm_Correlation1ROI | 0.03 | 0.2733 | 0.092 | 0.004* |
| Tumor ROI | Texture | LBP |
| LBP-3D-m1_glszm_LargeAreaEmphasis2ROI | 0.0298 | 497.883 | 349.1798 | 0.000* | W | Tumor-to-brain interface ROI | Texture | LBP |
| LBP-3D-k_glrlm_RunEntropy1ROI | −0.0266 | 4.1129 | 0.2879 | 0.031* |
| Tumor ROI | Texture | LBP |
| wavelet-LH_gldm_LargeDependenceLowGrayLevelEmphasis1ROI | 0.0245 | 0.016 | 0.0189 | 0.000* | W | Tumor ROI | Texture | Wavelet |
| wavelet-LH_glszm_SizeZoneNonUniformityNormalized2ROI | −0.0196 | 0.5121 | 0.0603 | 0.000* |
| Tumor-to-brain interface ROI | Texture | Wavelet |
| exponential_glrlm_ShortRunLowGrayLevelEmphasis2ROI | −0.0176 | 0.1056 | 0.0286 | 0.005* | W | Tumor-to-brain interface ROI | Texture | Exponential |
| LBP-3D-k_glszm_LargeAreaHighGrayLevelEmphasis1ROI | −0.016 | 36,713.5462 | 24,915.5914 | 0.021* |
| Tumor ROI | Texture | LBP |
| LoG-sigma-4-0-mm-3D_firstorder_Skewness1ROI | −0.0116 | 0.0814 | 0.4851 | 0.033* |
| Tumor ROI | First-order | LoG |
| logarithm_glrlm_RunLengthNonUniformityNormalized2ROI | −0.0098 | 0.8039 | 0.0714 | 0.000* |
| Tumor-to-brain interface ROI | Texture | LoG |
| logarithm_glcm_Correlation1ROI | 0.0094 | 0.7269 | 0.1057 | 0.000* | W | Tumor ROI | Texture | LoG |
| LBP-3D-k_glszm_ZonePercentage1ROI | 0.0064 | 0.0224 | 0.0075 | 0.001* |
| Tumor ROI | Texture | LBP |
| exponential_glcm_Idn2ROI | −0.0031 | 0.9767 | 0.011 | 0.007* |
| Tumor-to-brain interface ROI | Texture | Exponential |
| square_gldm_SmallDependenceLowGrayLevelEmphasis1ROI | −0.0018 | 0.0124 | 0.0084 | 0.000* | W | Tumor ROI | Texture | Square |
ROI, region of interest; W, Wilcoxon test; t, t-test.
*p < 0.05.
The result of multiple logistic regression.
| Features | Coef |
|
|
|---|---|---|---|
| Peritumoral edema | 1.3079 | 42.592 | <0.0001 |
| Tumor location | −0.0633 | 33.021 | 0.0046** |
| Hyperostosis | 0.8289 | 7.594 | 0.0309* |
| T2-weighted signal | −0.0210 | 7.075 | 0.0095** |
| CSF cleft sign | −1.3991 | 8.493 | 0.0063** |
| Rscore_1ROI | 1.5849 | −10.338 | 0.0013** |
| Rscore_2ROI | 4.1189 | −7.516 | <0.0001 |
*p < 0.05, **p < 0.01.
Figure 6Clinical semantic and radiomics nomogram (CSRN) and its calibration curves. (A) Nomogram; (B) correction curve of the training set; (C) calibration curves of the test set.
Figure 7Confusion matrixes of the five models. Test set: CSRN (A1), TRM (B1), TbRM (C1), CSM (D1), and TCTbRM (E1); training set: CSRN (A2), TRM (B2), TbRM (C2), CSM (D2), and TCTbRM (E2). CSRN, clinical semantic and radiomics model/nomogram; TRM, tumoral radiomics model; TbRM, tumor-to-brain interface radiomics model; CSM, clinical semantic model; TCTbRM, tumor combined tumor-to-brain interface radiomics model.
Figure 8Performance of the five models. (A) ROC curve of the training set; (B) ROC curve of the test set; (C) DCA curve of the training set; (D) DCA curve of the test set. ROI, region of interest; DCA, decision curve analysis.
Comparison of the performance of the models.
| Model | Training set ( | Test set ( | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AUC (95% CI) |
| ACC | SEN | SPE | NPV | PPV | AUC (95% CI) |
| ACC | SEN | SPE | NPV | PPV | |
| CSRN | 0.905 (0.863–0.9472) | – | 0.854 | 0.884 (0.813–0.935) | 0.81 (0.699–0.887) | 0.816 (0.717–0.893) | 0.877 (0.800–0.931) | 0.895 (0.828–0.962) | – | 0.826 | 0.788 (0.653–0.889) | 0.882 (0.725–0.967) | 0.732 (0.579–0.914) | 0.911 (0.783–0.957) |
| TRM | 0.762 (0.695–0.829) | 0.0004** | 0.689 | 0.636 (0.544–0.722) | 0.77 (0.656–0.855) | 0.573 (0.478–0.707) | 0.811 (0.713–0.864) | 0.701 (0.588–0.814) | 0.004** | 0.686 | 0.635 (0.490–0.764) | 0.765 (0.588–0.893) | 0.578 (0.430–0.778) | 0.805 (0.645–0.885) |
| TbRM | 0.829 (0.771–0.888) | 0.039* | 0.773 | 0.818 (0.738–0.882) | 0.701 (0.586–0.800) | 0.711 (0.605–0.807) | 0.812 (0.722–0.878) | 0.769 (0.671–0.867) | 0.039* | 0.709 | 0.635 (0.490–0.764) | 0.84 (0.655–0.932) | 0.596 (0.449–0.813) | 0.846 (0.691–0.911) |
| CSM | 0.828 (0.769–0.887) | 0.037* | 0.808 | 0.909 (0.843–0.954) | 0.649 (0.53–0.755) | 0.820 (0.710–0.883) | 0.803 (0.714–0.894) | 0.761 (0.658–0.863) | 0.033* | 0.767 | 0.769 (0.632–0.875) | 0.765 (0.588–0.893) | 0.684 (0.527–0.847) | 0.833 (0.687–0.913) |
| TCTbRM | 0.860 (0.807–0.913) | 0.072 | 0.808 | 0.785 (0.701–0.855) | 0.844 (0.744–0.917) | 0.714 (0.616–0.836) | 0.888 (0.809–0.927) | 0.817 (0.723–0.910) | 0.046* | 0.791 | 0.885 (0.766–0.956) | 0.647 (0.46–0.803) | 0.786 (0.610–0.890) | 0.793 (0.645–0.917) |
ACC, accuracy; SEN, sensitivity; SPE, specificity; NPV, negative predictive value; PPV, positive predictive value.
*Indicates significant difference after the DeLong test.
*p< 0.05, **p < 0.01.